Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX: Almonertinib With or Without Chemotherapy as Adjuvant Treatment for EGFR+ Stage II-IIIA NSCLC
NCT04762459Phase 3Enrolling by invitation
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of almonertinib in non-small cell lung carcinoma (NSCLC) (3 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Disease Free Survival up to 100 months. Started Aug 2021; status: enrolling by invitation.
02
Drugs
almonertinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT04762459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762459.